Esophageal and Gastroesophageal Junction Carcinoma

Esophageal and Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 460
Recruiting: 254
Ph III recruiting: 40
Growth YoY: +36.1%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (120)

clinicaltrialsPublishedShowing 51–100 of 156 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05476380	Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma	unknown	Phase 2	39	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Jul 27, 2022	clinicaltrials
NCT05469061	Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC	unknown	Phase 2	17	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	1